Juan Canton
Neurology with Special Qualifications in Child Neurology · Warwick, RINPI 1023182383
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Corium, LLC at 36.0% of the total. Reporting peaked in 2023 at $1,107 and has fallen 57.7% since, to $468 in 2025.
Across 101 payments — averaging $25.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$922
- SK Life Science, Inc.$329
- Supernus Pharmaceuticals, Inc.$278
- Collegium Pharmaceutical, Inc.$186
- Otsuka Pharmaceutical Development & Commercialization, Inc.$112
- Biogen$110
- plus $625 from 11 others
What the payments were for
- Food & beverage$2,54099%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 32 | $922 |
| SK Life Science, Inc. | 15 | $329 |
| Supernus Pharmaceuticals, Inc. | 16 | $278 |
| Collegium Pharmaceutical, Inc. | 4 | $186 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $112 |
| Biogen | 2 | $110 |
| Tris Pharma Inc | 4 | $109 |
| Azurity Pharmaceuticals, Inc. | 1 | $108 |
| AbbVie | 5 | $105 |
| Gilead | 1 | $66 |
| Pfizer | 3 | $60 |
| Sunovion Pharmaceuticals Inc. | 6 | $54 |
| Ironshore Pharmaceuticals Inc. | 3 | $50 |
| Neos Therapeutics, LP | 2 | $26 |
| Promius Pharma LLC | 1 | $21 |
| Novartis | 1 | $19 |
| Travere Therapeutics, Inc. | 4 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neurology with special qualifications in child neurology providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AptiomEslicarbazepine Acetate | 14 | $15,804 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 52 | $1,854 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 23 | $1,353 |
| Topiramate | 18 | $423 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sunovion Pharmaceuticals Inc.Aptiom | $54 | $15,80414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neurology with special qualifications in child neurology providers in Rhode Islandon file to place this against a meaningful peer group, so we don't.
Other neurology with special qualifications in child neurology in Warwick
- John GaitanisProvidence$45K
- Andrea YounesCumberland$26K
- Maria YounesCumberland$13K
- Luca BartoliniProvidence$798
- Duyu NieProvidence$389
- Tomo TaruiProvidence$107
- Gita HarappanahallyProvidence$17
- Ana Albuja PonceProvidence$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.